NCT06267092

A Study of How CagriSema Works on Appetite in People With Excess Body Weight

An Investigation of the Effect of Cagrilintide and Semaglutide Combination Treatment (CagriSema) on Appetite and Functional Brain Activity in People With Overweight or Obesity

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 164 (actual)
• Sponsor: Novo Nordisk A/S · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

Part A: The study will look at participants appetite and energy intake and also look at the mechanisms of brain associated with appetite and food intake. Participants will not get any medicine and will be in a group that will be compared to another group receiving a weight-loss medicine. The study will last for about 6 months. Part B: The study will look at how CagriSema works on participants appetite and energy intake and will be compared with a ''dummy'' medicine. The study will also look at how participants brain works when participants take the medicine. Participants will either get CagriSema or ''dummy'' medicine.

Conditions

• Overweight
• Obesity

Interventions

Type	Name	Description
OTHER	No treatment given	Participants will not get any medicine during this study.
DRUG	Cagrilintide and Semaglutide	Participants will receive subcutaneous (s.c.) injections of Cagrilintide and Semaglutide.
DRUG	Placebo	Participants will receive subcutaneous (s.c.) injections of placebo matched to Cagrilintide and Semaglutide.

Timeline

• Start date: 2024-02-15
• Primary completion: 2025-04-07
• Completion: 2025-12-08
• First posted: 2024-02-20
• Last updated: 2026-01-08

Locations

1 site across 1 country: Germany

Regulatory

• FDA-regulated drug study